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Abstract
Cells from patients with acute myeloid leukaemia (AML) that remain dormant and protected
by stromal cells may escape effects of chemotherapy. We modelled dormancy in vitro and
investigated the ability of Bcl-2 inhibitors ABT-199 and ABT-737 to overcome
chemoprotection of dormant cells. CD34-enriched primary AML cells with aberrant
leukaemia-associated phenotypes (LAPs) were cultured on stromal cells. The chemosensitivity
of dormant (PKH26high), CD34+, LAP+ cells was ascertained by 5-colour flow cytometric
counting after 12 days. The PKH26high, CD34+, LAP+ subset retained clonogenic capacity.
The dormant fraction was completely resistant to ara-C (P=0.007). However, ABT-199 and
ABT-737 were able to reduce the dormant fraction by 84% and 80% respectively of their
effects on proliferating counterparts. In conclusion, we have elaborated a system for
quantifying chemosensitivity in LAP+ dormant leukaemia cells thought to contribute to disease
relapse, and shown sensitivity of dormant LAP+ cells to ABT-199 and ABT-737 in this system.
4Introduction
Relapse is common in patients with acute myeloid leukaemia after remission-induction with
nucleoside analogue/anthracycline-based chemotherapy. The cells which give rise to relapse
are likely to have evaded the effects of treatment by lying dormant [1, 2]. The concept of a
dormant cancer cell can initially seem counter-intuitive, but in AML the presence of these
cells has been substantiated by both functional and phenotypic evidence [1, 2, 3, 4, 5, 6, 7].
Dormant AML cells are concentrated adjacent to stromal cells [1, 8]. Protection of AML cells
from chemotherapeutic drugs by proximity to stromal cells has been shown for several
compounds, including the standard chemotherapeutics daunorubicin and cytarabine [1, 9, 10]
as well as FLT3 inhibitors [5, 11]. Alvares and colleagues combined dormancy and niche in a
single model and were able to demonstrate resistance to a FLT3 inhibitor in a dormant AML
subpopulation cultured in vitro on stromal cells [5].
A potential novel approach to AML therapy is to target the B-cell lymphoma 2
(BCL2) protein family and thus directly induce apoptosis [12]. Anti-apoptotic members of
the BCL2 family, i.e. BCL2, BCLXL, BCLW, BFL1 (A1), BCLB and MCL1, are considered
as guardians of mitochondrial integrity by opposing pro-apoptotic BCL2 family proteins. In
theory, oncogenic stresses may upregulate pro-apoptotic pathways, and therefore the
successful cancer cell needs to have just enough functioning anti-apoptotic molecules to hold
apoptosis in check. Cancer cells may therefore be dependent on (“addicted to”) survival gene
expression and/or be “primed” by pro-apoptotic BH3 only proteins to readily undergo
apoptosis once the anti-apoptotic family members are inhibited [13, 14, 15]. ABT-737 and
ABT-199 (a reverse engineering version of ABT-737’s oral form ABT-263 that has high
affinity for BCL-2 and lower affinity for BCLXL), have exhibited promising anti-cancer
activities in vitro and in vivo [16, 17] including activity against AML cells [18, 19, 20, 21,
22]. Furthermore, these agents are found to significantly potentiate certain other
5chemotherapeutics [22, 23, 24, 25, 26, 27, 28, 29], suggesting a promising future for novel
drug combinations.
In the current study, we compare the sensitivities of proliferating and dormancy-enriched
primary AML cells to ABT-199 and ABT-737. We show that aberrant phenotypes can
persist through several days of culture on MS-5 stromal cells and we were able to use this
finding in order to quantify dormant AML cells labelled with the proliferation marker PKH26
with and without the addition of ABT-199 and ABT-737.
Materials and methods
Materials
Antibodies were from BD Biosciences (Cowley, UK) and other reagents were from Sigma-
Aldrich (Poole, UK), unless otherwise stated. TG02, originally designated SB1317, was
kindly provided by Tragara Pharmaceuticals (Carlsbad, CA, USA). ABT-737 was from
Sequoia Research products (Pangbourne, UK). ABT-199 was from Active BioChem (Hong-
Kong). All three agents were reconstituted in Dimethyl sulfoxide (DMSO) and stored at 10
mM.
AML Patient Samples
Fresh or cryopreserved bone marrow or peripheral blood samples of patients presenting with
de novo or relapsed AML were collected after written consent at diagnosis at the Nottingham
University Hospitals. Use of these samples was approved by the Nottingham Research Ethics
Committee and the samples were anonymised. Mononuclear cells were isolated using a
standard density gradient/centrifugation method with Histopaque and red blood cells depleted
from the sample using ammonium chloride. Cryopreserved samples kept in liquid nitrogen
were thawed and rested in RPMI-1640 medium (Sigma-Aldrich, Poole, UK) enriched with
620% FCS (First Link, UK), for 60 to 90 minutes before experimental handling. Only samples
with > 85% post-rest viability, assessed by trypan blue exclusion, were used. Leukaemia
associated phenotypes (LAPs) were assessed by published methods [30] prior to culture.
12-day Leukaemic cultures on stroma
MS-5 stromal cells [31] were maintained at a density of 5 x 104/mL in α-minimum essential 
medium (α-MEM; Gibco, Paisley, UK), supplemented with 10% heat-inactivated FCS, 1% 
penicillin/streptomycin and 2mmol/L L-glutamine. For 12-day co-culture studies, MS-5 cells
were sub-cultured at 2 x 104/mL on a gelatin-coated 12-well flat-bottom plate for 24 to 48
hours to form a monolayer before addition of AML cells. CD34+ cells from fresh or
cryopreserved AML samples were enriched by magnetic bead separation using Mini-MACS
CD34 isolation kit (MiltenyiBiotec, Bisley, UK) and then labelled with the permanent cell
membrane dye PKH26 according to manufacturers’ instructions. Labelled cells (at 2 x 106
cells/mL) were added to the MS-5 feeder layer and co-cultured in Gartner Medium [32].Cells
were kept in culture for 12 days and demi-populated on day 7. Drugs were added to cells on
day 8 of the cell culture. On day 12, cells were harvested and processed for clonogenic assay
and flow cytometric assessment as detailed below.
Enumeration of viable, dormant LAP positive AML cells
Immunophenotyping assays were performed on a FACS Canto II cytometer equipped with
FACS-DIVA II software (Becton Dickinson, San Jose, USA). On days 0,7 and 12, cells were
labelled with anti-CD45-APC.CyTM7 and anti-CD34-APC clone BIRMA-K3 (Alere Ltd,
Stockport, UK). Additional antibodies used to identify LAPs were anti-CD7- FITC (Beckman
Coulter, Marseille, France) or anti-CD19-FITC. 7-AAD was used at 5μg/mL to exclude non-
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standard for cell counting.
Methylcellulose Colony Formation (CFU) Assay
Following 12-day culture, cells were labelled as above and sorted on a MoFlo™ XDP Cell
Sorter (Beckman Coulter, Fullerton, CA, USA). Sorted cells were washed, re-suspended in
StemSpan Expansion medium with 1% Stemspan CC100 cytokine cocktail for 3-4 days and
transferred to Methocult H4034 colony medium (all from Stem Cell Technologies, Grenoble,
France). Cells were plated onto 96-well flat-bottom plates at 2 x 104 cells/100 µL in
triplicates and were incubated at 37 ˚C in 5% CO2 for 14 days. Colonies of >50 cells were
counted.
Statistics
Data were analysed using SPSS 21 software package (Chicago, IL, USA).
Results
Dormant primary leukaemia cells retaining clonogenic capacity can be identified after 12
days of co-culture and are effectively targeted by ABT-737 and ABT-199
We established and validated a system for measuring the chemosensitivity of dormant
primary leukaemia cells (Figure 1). After labelling CD34+ primary cells with PKH26 and
culturing on MS-5 stromal cells for 12 days, we ascertained that the leukaemic nature of the
cells following culture could be assured through the selection of samples with a major
leukaemia associated phenotype (LAP). The aberrant CD34/CD7 and CD34/CD19 status of
cells identified in presentation samples was maintained in the dormant subset throughout the
12 days of culture (Table I). We further ascertained the clonogenicity of sorted CD45
8dimCD34+LAP+PKH26high (dormant) subpopulation following the 12 day culture. We found that
this subpopulation retained almost all of the clonogenic capacity compared to the CD45dimCD34+/-
LAP+PKH26low cells that had already divided in vitro (Table II). In two samples, a comparison of
stromal support by MS-5 and by mesenchymal stem cells was made, with healthy human adult BM-
MSCs cultured as described [33]. Clonogenicity of cells cultured by both methods was measured, but
major differences were not observed (Table II).
Drugs were added after eight days to primary AML cells in the MS-5 co-culture system. The
drug concentrations used were chosen on the basis that these were the average 72 hour IC40 values
determined in preliminary assays in suspension culture (data not shown). Chemosensitivity was
ascertained by 5-colour flow cytometric counting using a suspension of CytoCountTM fluorospheres as
a reference population. Six samples were studied with this protocol as shown in Table III. We have
previously shown that the multi-kinase inhibitor TG02, which targets transcriptional cyclin-dependent
kinases, has efficacy against dormant AML cells [7] and we used this agent as a positive control. 200
nM Ara-C reduced the cell number by 49% in the cycling fraction, but there was no cell reduction at
all in the dormant fraction (P=0.007, Figure 2). In contrast, exposure to ABT-199, ABT-737 and
TG02 markedly reduced the number of both dormant and cycling cells. Although there is some
favouring of cycled cells with these agents (Table III), we found that ABT-199 and ABT-737 were
able to reduce the dormant cell fraction by 84% and 80% respectively of their effects in proliferating
counterparts.
Discussion
The presence of dormant cells within a leukaemic clone presents the chemoresistance researcher with
a distinct challenge, as most anti-neoplastic drugs have been designed to target proliferating cells as a
surrogate for tumour cells, and therefore highly chemoresistant dormant cancer cells do not fit into the
mainstream chemotherapeutic paradigm.
9We built on a model previously described by Alvares and colleagues for identifying dormant
cells grown on MS-5 stromal cells [5]. Additionally we used LAP markers to identify leukaemic cells
against a background of potentially normal haematopoietic cells. We chose 12 days to approximate
the length of time an AML cell would need to remain dormant to resist a course of chemotherapy.
Guan and colleagues had demonstrated that the majority of ex vivo dormant AML cells rapidly re-
enter the cell cycle in vitro [4], and thus phenotypic labelling of freshly isolated or thawed cells with
dormancy markers might greatly overestimate the proportion of cells that would remain dormant,
whereas the 12 day culture allowed us to be more confident that we were studying a clinically relevant
subset of these cells. Our evaluation of this model indicated that not only could the expression of
some LAP markers persist in the 12-day culture, but also that some dormant LAP+ leukaemia cells
maintained their clonogenic potential, thus alleviating our concern that the in vitro conditions may
have rendered the cells senescent. A second argument against the in vitro induction of senescence in
our model is that senescent cells are characterised by increased size and granularity and therefore have
increased low-angle and orthogonal light scatter (forward scatter and side scatter) on flow cytometric
analysis [34], whereas the CD34+/PKHhigh cells selected for analysis in our experiments retained low
scatter properties – this is illustrated in the Figure 1 gating. The variability in proliferative abilities
between cells within a single sample has been appreciated for several decades [35, 36], but the
reasons why clonogenic cells can remain dormant in culture with stromal cells and then form colonies
in semi-solid medium suggests a contribution from the stromal cells to the state of dormancy. The
retention of clonogenic potential in PKHhigh, but not PKHlow cells was very marked, and the use of
LAP markers in the sorting process ensured that non-leukaemic cells were not affecting the output.
The efficacy of ABT-199 and ABT-737 in dormant cells cultured on MS-5 was at least 80%
of their efficacy against cycled cells and the contrast to Ara-C, which completely failed to eradicate
dormant primary cells when cultured on stromal cells, was pronounced. Primary samples differ
enormously in their rates of cycling and therefore the proportion of cells likely to be vulnerable to ara-
C [37]. Morevoer, the osteoblastic niche has been shown to protect a dormant subset of AML cells
from this drug [1]. The in vitro model system used thus enabled us to incorporate a protective stromal
microenvironment, to discriminate between leukaemic and residual normal cells based on LAPs and
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to contrast the effects of novel agents with the established drug araC which is selective for
proliferating cells. The success of this model in assessing drug sensitivity in both cycling and
dormant cell compartments, whilst unlikely to eliminate the need for in vivo models, has the potential
to refine the number and scale of such studies.
2/6 samples used in this study were from patients with complex cytogenetics. A further
patient with normal cytogenetics was studied with refractory disease. A fourth patient had
transformed CMML and was unsuitable for intensive treatment. There were no good cytogenetic risk
samples included. The high proportion of CD7+ aberrant phenotypes probably contributed to this
bias. There have been at least 20 studies of aberrant CD7 expression in AML with very mixed results
as to its prognostic value. However, the majority consensus appears to be that it is associated with
normal or adverse cytogenetics and with multidrug resistance [38, 39]. This is therefore an interesting
cohort to study with a view to identifying therapies from which hard-to-treat patients might benefit.
Evidence that BCL2 is therapeutically relevant in AML was established in our laboratory and
by others nearly two decades ago [40, 41], but has been refined recently with the emergence of first
ABT-737 and then ABT-199 as research tools and as drugs. An additional important discovery is that
cells with low levels of reactive oxygen species (ROS-low), functionally defined as leukaemic stem
cells, aberrantly over-express BCL-2 and are selectively targeted by ABT-737 [20]. ROS-low AML
cells are enriched for dormant (Ki-67 negative) cells and therefore overlap the subpopulation we have
investigated in the current work. An observation that AML cells with high BCL2 expression tend to
have an impaired ability to enter the cell cycle has also been documented [42]. ABT-737 causes
prolonged thrombocytopenia associated with BCLXL targeting, but ABT-199, which is more specific
for Bcl-2, is of huge clinical interest: one report has been published [43] and 12 clinical studies are
currently (September 2017) listed for ABT-199 (also known as venetoclax) in AML by
clinicaltrials.gov. Our data suggest that this agent may have efficacy against cells protected by niche
and dormancy. Analysis of post-treatment biopsies would be of great help to establish the cell cycle
status of residual cells and thus whether venetoclax can eradicate dormant leukaemic cells in the
clinic.
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In summary, we have established and validated a system for the direct comparison of the
chemosensitivity of intra-sample cycling and dormant leukemic cells. Using this methodology we
have shown a differential response to araC in cycling versus dormant leukaemia cells, however ABT-
199 and ABT-737 demonstrated effective targeting of both cellular compartments emphasising the
potential importance of these agents in the clinical eradication of all leukaemic cells.
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FIGURE LEGENDS
Figure 1. 12 day culture of dormant primary AML cells
(A) Schema for dormant leukaemia cell chemosensitivity assay.
(B) and (C). Flow cytometric gating for dormant cells chemosensitivity assay. (B) On Day 0 the
fluorescence of PKH-labelled CD34+ cells is recorded. (C) On day 12, (i) scatter, (ii) 7-AAD and (iii)
CD45-gated plots combine to distinguish viable myeloid cells. (iv) LAP positive cells are identified
(CD7 in this example). (v) Although most cells have decreased/lost PKH-26 and/or CD34 compared
with Day 0, a sub-population of non-dividing (PKH26high) cells is detected in CD34+, LAP+ myeloid
blasts.
Figure 2. Sensitivity to ABT-199 and ABT-737 in 12 day culture of dormant primary AML cells
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The bar chart shows percentage surviving cells compared with untreated controls in the dormant and
cycled fractions of AML blasts after 12 days culture on MS-5 stromal cells (n=5, mean + standard
deviation). 100 nM ABT-199, 100 nM ABT-737, 25 nM TG02 or 200 nM Ara-C were added on Day
8.
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Table I. Retention of aberrant surface marker (LAP) expression after 12-day culture of
primary AML cells
AML
sample
Days in
culture
LAP
marker
LAP cells as
% of total
AML cells
LAP cells in the
CD45dimCD34+PKH26high
compartment (%)
603 Day 0 CD7 85.5 79.1
Day 7 68.1 77.4
Day 12 13.8 77.2
596 Day 0 CD7 84.6 89.1
Day 7 73.6 83.4
Day 12 12.5 83.9
582 Day 0 CD19 43.1 54.7
Day 7 38.5 44.8
Day 12 37.3 41.3
536 Day 0 CD7 61.3 85.1
Day 7 55.4 84.3
Day 12 53.9 80.4
444 Day 0 CD7 86.4 98.4
Day 7 73.1 87.2
Day 12 41.4 86.9
601 Day 0 CD7 32.9 92.1
Day 12 26.3 72.9
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Table II. Colony frequency in sorted fractions from de novo AML samples after 12-day
culture
AML
sample
Subset Total
sorted
cells
Total
colony
count
Standardised
colony growth
rate (per
10,000 cells)
603 dormant 1471 11 75
cycled 344 0 0
596 dormant 717 17 237
cycled 8510 2 2
582 dormant 6530 31 47
cycled 9830 3 3
536 dormant 10390 55 53
cycled 230750 3 1
444 dormant 6306 54 86
cycled 10757 0 0
603 MSC* dormant 1070 4 37
cycling 128 0 0
596 MSC* dormant 352 15 426
cycling 3359 1 3
*Although MS-5 cells were used in all cases, in two cases (#603 and #596) we also used primary
mesenchymal stem cells (MSC) so that the clonogenic yield from each support system could be
compared.
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Table III. Samples studied in 12-day culture
Demographics
Sample 603 582 596 444 536 601
patient age 64 42 67 71 40 61
LAP CD34
CD7
CD34
CD19
CD34
CD7
CD34
CD7
CD34
CD7
CD34
CD7
NPM1 status wildtype wildtype mutant wildtype wildtype wildtype
FLT3 ITD status wildtype mutant mutant wildtype wildtype mutant
FLT3 point
mutation status
wildtype wildtype wildtype wildtype wildtype wildtype
Cytogenetics complex MLL,
+11
46XX
del(2)(q11q21)
der(7)t(1;7)(q2q
22),
add(11)(q2)[9]
normal complex normal
%CD34+ 76 76 10 91 16 10.5
%CD34+ CD38- 0.2 0.031 2.407 not done 0.04 2.1
category de novo de novo de novo refractor
y
relapse
after
transplant
transformed
CMML
Percent cell
survival
araC
cycled 52 51 62 97 48 n/a*
dormant 104 117 105 111 97 100
ABT-737
cycled 43 8 31 39 37 n/a*
dormant 49 39 46 32 60 61
ABT-199
cycled 39 30 29 7 32 n/a*
dormant 47 36 40 14 60 42
TG02
cycled 48 17 40 59 42 n/a*
dormant 65 41 62 47 81 73
* This sample lacked a cycled subset after 12 days. (It was therefore excluded from the comparative
graph)
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